Kinarus Therapeutics

SIX: KNRS

Market CapCHF10m

Last Close CHF0.01

Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.

More Kinarus Therapeutics content >

Investment summary

Kinarus received a notice of allowability from the US Patent and Trademark Office (USPTO) for its patent application No. 16/500,504 (‘methods of preventing or treating ophthalmic diseases’) covering its orally dosed lead drug candidate KIN001 for its lead indication to treat wet age-related macular degeneration (wet AMD). This method of use patent is on top of the USPTO-granted composition-of-matter Patent No. 11285155, which is designed to protect the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. We view this development as positive for Kinarus as it strengthens the intellectual property position of KIN001 as the company works towards starting a Phase II study with the drug in wet AMD in the coming months, upon the attainment of the necessary financing.

Y/E Dec
Revenue (CHFm)
EBITDA (CHFm)
PBT (CHFm)
EPS (fd) (CHFc)
P/E (x)
P/CF (x)
2020A 0.0 (1.5) (1.5) (31.17) N/A N/A
2021A 0.0 (5.1) (4.9) (0.41) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

Upon availability of new funding, Kinarus plans to start a Phase II study in wet AMD, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.

Last updated on 30/11/2022
Content on Kinarus Therapeutics
Kinarus Therapeutics – USPTO allows method-of-use KIN001 patent
Healthcare | research Flash note | 24 November 2022
Healthcare business graph data and growth, Insurance Healthcare. Doctor analyzing medical of business report and medical examination with network connection on laptop screen.
Kinarus Therapeutics – KINETIC study discontinued
Healthcare | research Flash note | 3 October 2022
Healthcare business graph data and growth, Insurance Healthcare. Doctor analyzing medical of business report and medical examination with network connection on laptop screen.
Kinarus Therapeutics – H122 results reflect continued progress
Healthcare | research Flash note | 5 September 2022
Healthcare business graph data and growth, Insurance Healthcare. Doctor analyzing medical of business report and medical examination with network connection on laptop screen.
View more
Register to receive research on Kinarus Therapeutics as it is published
Share price graph
Balance sheet
Forecast net debt (CHFm) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (8.2) (67.9) (87.1)
Relative* (10.6) (68.6) (86.0)
52-week high/low CHF0.1/CHF0.0
*% relative to local index
Key management
Dr. Alexander Bausch CEO
Subhasis Roy CFO